Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 1;39(1):43-49.
doi: 10.1097/MOG.0000000000000892. Epub 2022 Nov 3.

Check this out: treatment paradigms in immune-checkpoint inhibitor colitis

Sara Kiparizoska  1 , Megan E Murphy  2   3 , Mark C Mattar  2
Affiliations
Review

Check this out: treatment paradigms in immune-checkpoint inhibitor colitis

Sara Kiparizoska et al. Curr Opin Gastroenterol. .

Abstract

Purpose of review: Immune checkpoint inhibitors (ICI) have become a pillar of cancer therapy for many people around the world. However, up to two-thirds of all patients undergoing ICI therapy will have immune-related adverse events (irAEs), including immune-checkpoint inhibitor colitis (ICIC). This review summarizes the most valuable and currently available information about the mechanism, diagnosis, and management of ICIC.

Recent findings: Recent findings include several developments on the leading theories for the mechanisms of ICIC such as the role of the gut microbiome. New emerging therapy strategies include tocilizumab, ustekinumab, mycophenolate mofetil, and calcineurin inhibitors.

Summary: The occurrence of irAEs remains a limiting factor for the use of immunotherapy in cancer treatment. Prompt diagnosis of ICIC with endoscopy and histologic confirmation can lead to early utilization of known effective treatments such as corticosteroids, infliximab, vedolizumab, and other emerging therapy strategies. We summarize the key points of this review article in our abstract video, Supplemental Digital Content 1, http://links.lww.com/COG/A44.

PubMed Disclaimer

References

    1. Tran T, Tran NGT, Ho V. Checkpoint inhibitors and the gut. J Clin Med 2022; 11:824.
    1. Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases 2019; 7:405–418.
    1. Tawbi HA, Schadendorf D, Lipson EJ, et al. RELATIVITY-047 Investigators. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022; 386:24–34.
    1. Dobosz P, Dzieciątkowski T. The intriguing history of cancer immunotherapy. Front Immunol 2019; 10:2965.
    1. Tang L, Wang J, Lin N, et al. Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol 2021; 12:800879.

MeSH terms

Substances